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ABSTRACT
Background. Evidence-based tools are necessary for sci-
entifically improving the way MTBs work. Such tools are
available but can be difficult to use. This study aimed to
develop a robust observational assessment tool for use on
cancer multidisciplinary tumor boards (MTBs) by health
care professionals in everyday practice.
Methods. A retrospective cross-sectional observational
study was conducted in the United Kingdom from
September 2015 to July 2016. Three tumor boards from
three teaching hospitals were recruited, with 44 members
overall. Six weekly meetings involving 146 consecutive
cases were video-recorded and scored using the validated
MODe tool. Data were subjected to reliability and validity
analysis in the current study to develop a shorter version of
the MODe.
Results. Phase 1, a reduction of the original items in the
MODe, was achieved through two focus group meetings
with expert assessors based on previous research. The 12
original items were reduced to 6 domains, receiving full
agreement by the assessors. In phase 2, the six domains
were subjected to item reliability, convergent validation,
and internal consistency testing against the MODe-Lite
global score, the MODe global score, and the items of the
MODe. Significant positive correlations were evident
across all domains (p\ 0.01), indicating good reliability
and validity. In phase 3, feasibility and high inter-assessor
reliability were achieved by two clinical assessors. Six
domains measuring clinical input, holistic input, clinical
collaboration, pathology, radiology, and management plan
were integrated into MODe-Lite.
Conclusions. As an evidence-based tool for health care
professionals in everyday practice, MODe-Lite gives can-
cer MTBs insight into the way they work and facilitates
improvements in practice.
Multidisciplinary tumor boards (MTBs) are the gold
standard of cancer care delivery across the world.1 The
accepted benefits of MTBs include improved adherence to
best clinical practice, reduced geographic variability,
timeliness of diagnostics and treatment, and improved
outcomes including survival.1,2 Indirect benefits have been
found including improved health care professional well-
being, education, and quality assurance.3
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The literature clearly shows that inefficiencies in MTB
processes are commonplace.1,3 Factors such as professional
hierarchies, lack of open discussion, failure to consider
holistic information or patient views, and lack of personal
knowledge of the patient all have an adverse impact on
effective clinical decision-making.4 Improvement research
has provided an evidence-based ‘‘tool kit’’ with which
MTB members can identify factors that promote or hinder
teams in reviewing patients holistically in a meeting and
make recommendations that are both clinically sound and
acceptable to patients.5,6
One such intervention is the MODe (Metric for the
Observation of Decision-Making in cancer multidisci-
plinary tumor boards), which has been used to understand,
assess, and improve MTB working Supplementary Fig. S1.
7–11 Development and validation of the tool have been
reported previously.4,7–9 The MODe has been used to
assess decision-making processes across different tumor
types in different countries (Table 1).7–19
The MODe has been applied to show that the ability of
an MTB to reach a clinical decision is associated with high-
quality comprehensive and necessary information (from
case history, radiology, pathology) available at the point of
decision-making, team contribution, and the order of cases
in a meeting.11,12 The MODe has been used to provide
objective validation of the impact that quality improvement
interventions such as meeting preparation, team training,
meeting breaks, improved chairing style, and room layout
has on outcomes including meeting time, ability to reach
management recommendations, and maintenance of deci-
sion-making quality during long meetings.12 Moreover,
using factor analysis, the MODe has demonstrated that a
complete patient profile and representation by all core
disciplines are necessary to maximize the ability of an
MTB to reach management recommendations for all
cases.9
Users of the MODe (Table 1) have provided a useful
critique of the tool applied to a range of clinical and
research settings. During real-life MTB meetings, it can be
difficult for observers to differentiate individual variables
when scoring.13,16 Moreover, previous content validation
of the MODe has suggested that fewer factors are desir-
able.9 This sentiment has been echoed by some of the
health care professionals we have trained to use the MODe
in clinical practice, who expressed a desire for a simpler
tool that can be used for clinical audit (unpublished data).
The current study aimed to produce a tool that would
retain and simplify the most important elements of the
MODe,7 and that could be used by health care staff, who
are ultimately the end users of MTB processes. We
therefore developed the MODE-Lite, a more user-friendly
version of the MODe, which is intended for use in clinical
practice to assist teams in quality improvement and
streamlining of processes. Specifically, the objectives of
this study were (1) to retain validity by involving experts in
tumor board improvement in the construction of the tool,
building on previous content validation of the MODe9
(phase 1), (2) to validate the MODe-Lite externally against
a validated measure of case complexity (MeDiC)20,21 in
line with previous research12 (phase 2), and (3) to ensure
feasibility and reliability by assessing the use of the
MODe-Lite via several teams of expert and novice users
across different tumor types (phase 3).
METHODS
Study Design
This study was a retrospective cross-sectional observa-
tional psychometric investigation.
Study Setting
The study took place across three university hospitals in
metropolitan areas of the United Kingdom between
September 2015 and July 2016. Availability sampling was
used to identify MTBs from the UK National Health Ser-
vice (NHS) that represent the most common cancer types.
Three MTBs were identified and participated in the study
including breast, colorectal, and gynecologic MTBs.
Participants
The study participants were 44 tumor board members:
15 breast, 15 colorectal, and 14 gynecologic professionals.
The tumor boards had the same composition of surgeons
(n = 12), oncologists (n = 6), cancer nurse specialists
(CNS) (n = 12), radiologists (n = 6), histopathologists (n =
5), and coordinators (administrative role, n = 3). The
groups were at the attending level, with an average 9 years
of experience (minimum, 2 years; maximum, 22 years). A
detailed team composition breakdown has been published
previously.12,22,23 Ethical approvals were given by the
North West London Research Ethics Committee and
locally by the participating hospitals as part of the original
research.23 Oral and written consents were given by the
team members.
All case discussions during the study period were video-
recorded, including discussions on suspected or confirmed
cancer. The study included 146 consecutive case discus-
sions from six tumor boards. The dataset is available on
Zenodo.24 The sample size was determined using G*Power
325 for a priori power analysis with a two-tailed test, an
effect size of 0.6, a probability of 0.05, and a power of
0.90.
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TABLE 1 Overview of literature using the Metric for Observation of Decision-Making (MODe)
Citation Country Tumor type Use of MODe Comments
Lamb et al.7 UK Urologic cancers Development and validation of
MODe; 5 meetings (112 cases)
Observed by surgeon and
psychologist
IRR: 112 cases, ICC 0.31-0.87
Scientific observational metrics can
be reliably used by medical and
non-medical observers in cancer
MTBs to assess team decision-
making.
Lamb et al.8 UK Urologic cancers MODe observational assessment
Cross validation with a 29-question
self-report
Observation of 164 cases in 5 MTBs
47 surveys from MTB members
(response rate 70 %)
The quality of teamworking and
clinical decision-making in
MTBs can reliably be assessed
using observational and self-
report metrics.
MTB members have good insight
into their own team performance.
Lamb et al.10 UK Urologic cancers MODe observational assessment
Assessing effect of sequential MTB
improvement interventions (e.g.,
MTBs checklist, MTB team
training, and written guidance)
Prospective longitudinal study: 16
months, 1421 patients
MODe can be used to evaluate the
impact of QI interventions on
MTB processes.
Jalil et al.14 UK Urologic cancers, colorectal cancer,
skin cancer, upper gastrointestinal
cancer, head and neck cancer
MODe observational assessment
Refinement of MODe
Validation of use for assessment of
video-recorded cases
683 multidisciplinary tumor board
case
-332 cases (9 urology MDMs) by 1
urologist
-224 cases (6 urology boards) by 2
urologists
-127 video-recorded case
discussions (5 tumor types, over 8
MDMs)
IRR: 224 cases, ICC[0.7
MODe scores correlate with
decision efficacy.
Video recordings offer a feasible,
reliable method of assessing how
MTBs work.
MODe can be used across different
tumor types
Novice users can be trained to use
MODe using video-recorded
MTB meetings.
Shah et al.15 UK Colorectal cancer Modification of MODe to cMDT-




267 cases across 11 MDMs at single
institution
IRR: 76 cases, ICC 0.79 (0.70-0.92)
MODe can be adapted for use in
specific tumor types, in this case





gynecologic, head and neck, liver
and biliary tract cancer,
lymphoma and myeloma, neuro-
oncologic, non-entity-specific
oncologic, non-entity-specific
surgical, thorax, and uro-
oncologic cancer
MODe was adapted for use in
German-speaking country
MODe observational assessment
249 cases across 29 MTBs
IRR: 39 cases, ICC.5 for all
domains by end of study
MODe can be adapted for different
languages and health care settings
and provides reliable
observational data.
Soukup et al.11 UK Breast cancer MODe observational assessment
Assessing effect of co-designed
intervention bundle (meeting
breaks, change of room layout,
meeting chair)
MODe can be used as part of ‘‘team
audit and feedback’’ to improve
teamwork in cancer care.
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Tool Development and Validation Phases
We developed MODe-Lite from the original MODe
instrument7 and its previous content validation9 positing a
reduction in the number of the original items. A multi-
phased approach was undertaken in developing MODe-
Lite.
In phase 1 (objective A), two meetings were held with
experts (B.W.L., a clinical researcher and consultant sur-
geon, and T.S., a clinical researcher and psychologist) with
more than 5 years of experience in the use of MODe and
evidence4,9,12 of proficiency with inter-assessor reliability
higher than 0.70.26 The aim was to design a new tool and to
assess its content validity against MODe’s previous content
validation.9
Table 1 (continued)
Citation Country Tumor type Use of MODe Comments
MTB with 15 members, 1335
patient reviews
Lumenta et al.18 Austria Mixed: not specified MODe adapted to German language
and culture as TB team
performance assessment tool
Clinical and nonclinical observers
244 patients in 27 MDMs
IRR: cohorts of 11–141 cases,
pairwise agreement 54–100 %
MODe was adapted to developed
TB team performance tool in
German-speaking country.
Used to enabled the assessment of
specialized multidisciplinary
tumor boards with a special focus
on teamwork patterns
Rosell et al.19 Sweden Rare cancers: multidisciplinary
tumor boards for penile cancer,
anal cancer, and vulvar cancer
MODe and MOT observational
assessment
Electronic survey of health
professionals from 6 MDMs
67 case discussions observed
125/241 (52 %) responses to survey
IRR: 76 cases, agreement 0.86
MODe was used in a non-English-
speaking health care setting.




UK Breast cancer MODe observational assessment
10 MDMs (346 patients).
IRR: 116 cases, ICC 0.73-0.93
Breast cancer MTB evaluation via
direct observation in a meeting is
feasible and reliable.
Soukup et al.12 UK Breast cancer, colorectal cancer,
gynaecologic cancer
Observational assessment of team
behaviors using 3 tools: MODe,
Bales Interaction Process
Analysis (Bales IPA), Measure of
Case-Discussion Complexity
(MeDiC).
3 MTBs with 44 members. 30
meetings filmed, 822 case
discussions
MODe can be used together with
other behavioral assessment
metrics to unravel sociocognitive
predictors of team DM quality.
MODe used in conjunction with
MeDiC can provide stratified
assessment of performance
accounting for case mix.




223 MTB case discussions across 41
MDMs at 6 hospitals
MODe can be adapted for use in
specific tumor types, in this case
to GO-MODe for gynaecologic
patients.
Soukup et al.4,9 UK Breast cancer, colorectal cancer,
urologic cancer
MODe Observational assessment
combined with exploratory factor
analysis and regression analyses
to assess predictors of treatment
decisionNon-clinical and clinical
observers4 teams observed, 1045
case discussionsIRR: 273 cases;
ICC = 0.71–0.92
MODe can be used with other
assessment tools to better
understand the anatomy of MDT
decsion making.
MTB, multidisclinary tumor board; IRR, ICC, interclass correlation coefficient; MDM, cMDT, GO-MDT
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In phase 2 (objective B), assessor 1 (B.W.L.) scored a
sample of 146 cases that had previously been assessed with
MODe using the revised shorter version of the tool
(MODe-Lite). The aim was to assess convergent validity
with the original tool.7 We hypothesized (H1) that the
MODe-Lite domains would correlate positively with the
relevant items of the original MODe,7 in line with the
factor model proposed in previous research.9 In addition,
we aimed to validate MODe-Lite externally against case
complexity as measured by the previously validated Mea-
sure of Case-Discussion Complexity (MeDiC).20,21 We
hypothesised (H2) that MODe-Lite would positively cor-
relate with the MeDiC tool, in line with the previous
research using the MODe instrument.12
In phase 3 (objective C), both assessors (B.W.L. and
T.S.) trained a new assessor (S.M., a consultant surgeon) in
the use of the shorter version (MODe-Lite) on video-
recorded tumor boards during two 2-h-long sessions. The
assessors (B.W.L. and S.M.), blinded to the each other’s
scores, scored a subset of 60 cases. Disagreements were
subsequently discussed during a single 2-h data-review
session to understand how the scoring of the shorter tool
could be improved. The aim was to determine feasibility
and inter-assessor reliability in the use of MODe-Lite.
Statistical Analysis
The validity of MODe-Lite was assessed using a widely
used measure, the item-content validity index (I-CVI).27,28
The criteria for item acceptability depends on the number
of experts rating the items.27,28 If the experts are fewer than
five, all five must agree for the item to be retained.27,28
We performed convergent validity analysis of MODe-
Lite by assessing the correlation between individual
domains and the original MODe instrument (the individual
items of MODe and the global score). We also used the
overall MODe-Lite score for the item-total correlation.
We assessed the reliability between the two assessors
(B.W.L. and S.M.) using kappa coefficients for categorical
items (i.e., the individual items of MODe-Lite) and inter-
class correlation coefficients (ICCs) for continuous items
(i.e., the global scores). For the ICCs, a generally accepted
reliability coefficient of 0.70 or higher was used,26 whereas
for the kappa coefficients, the following criteria applied:
fair agreement (0.21–0.40), moderate agreement
(0.41–0.60), substantial agreement (0.61–0.80), and almost
perfect agreement (0.81–1.00).29 Cronbach’s alpha was
calculated to assess the internal consistency for each
MODe-Lite domain (i.e., how closely related these




Table 2 shows summary statistics for the individual
domains of MODe-Lite across the entire dataset (n = 146)
comprising three tumor boards, namely, breast, colorectal
and gynecologic boards. The holistic input and clinical
collaboration domains scored lowest, indicating overall
lower quality. Pathology and clinical input scored highest,
indicating better quality.
Phase 1: Item Content Validation (Objective A)
Two focus group meetings were held between two
expert assessors (B.W.L. and T.S.) for content validation
using all 12 items from the original MODe instrument.7
Guided by the previous content validation of the MODe
tool with a large sample (n = 1045) using exploratory factor
analysis,9 the factor model containing clinical and holistic
(patient history; oncologists’, surgeons’, and nurses’
inputs; psychosocial information; comorbidities; patient
view), radiology (radiology information and radiologists’
inputs), and pathology (pathology information and
pathologists’ input) components received full agreement (I-
CVI = 1) for inclusion into MODe-Lite.
Because of the substantial research evidence supporting
holistic information1,4,5,9,11,30,31 and clinical collabora-
tion1,4,5,11,32–34 adequately captured in the assessments for
team quality improvements,10,11 it was agreed by the expert
assessors (I-CVI = 1) that they should be scored separately,
resulting in three domains: clinical input, holistic input, and
clinical collaboration. Pathology and radiology were
TABLE 2 Summary statistics for the MODe-Lite domainsa
MODe-lite domain M SD Mdn IQR Min Max
Clinical input 2.25 0.68 2 1 1 3
Holistic input 1.25 0.52 1 0 1 3
Clinical collaboration 1.76 0.76 2 1 1 3
Pathology 2.34 0.84 3 1 1 3
Radiology 2.15 0.96 3 2 1 3
Management plan 2.20 0.74 2 1 1 3
Global score 11.95 2.50 12 4 6 18
MODe, Metric for the Observation of Decision-making; MODe-Lite,
user-friendly version of the MODe; M, mean; SD, standard deviation;
Mdn, median; IQR, interquartile range; Min, minimum; Max,
maximum
aScore range for the individual domains is 1 to 3, and for the global
score it is 6 to 18. Higher scores indicate better quality. Note. Total
(n = 146), breast (n = 40), colorectal (n = 31), gynecologic (n = 75)
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retained as separate domains (I-CVI = 1), in line with the
factor analysis.9 Management plan, an outcome variable in
the factor analysis and previous research,9 also was
retained (I-CVI = 1) as a separate item. Therefore, a total of
six domains received full agreement for inclusion in
MODe-Lite by the expert assessors (I-CVI = 1) and were
subjected to further validity and reliability testing. The tool
is represented graphically in Fig. 1.
Phase 2: Item Convergent Validity, Reliability,
and External Validity (Objective B)
The six domains of MODe-Lite were next validated
against the global scores of MODe-Lite, the original
MODe,7 and the MeDiC tool,20,21 (in line with previous
research)12, respectively. All the MODe-Lite domains
showed significant positive correlation with the MODe-
Lite global score (Table 3), indicating good convergent
validity across all six domains. In addition, significant
positive correlation was evident against the global score for
the original MODe tool, indicating good external validity
and support for the H1 (i.e. MODe-Lite will correlate
positively with the relevant items of the original MODe).
The exception was pathology, for which the correlation
coefficient, although positive, did not reach statistical sig-
nificance. Significant positive correlation also was evident
against the global score for the MeDiC tool, further indi-
cating good external validity and support for the H2 (i.e.
MODe-Lite will correlate positively with the MeDiC tool
in line with previous research12).
Further external validation was performed against the
corresponding MODe items in line with the content vali-
dation in phase 1 and previous research.9 Table 4 shows
significant positive correlations throughout between the 6
MODe-Lite domains and their corresponding 12 MODe
items. This finding provided further support for H1.
The Cronbach alpha, measuring how closely related
each set of MODe items is as a domain of MODe-Lite, was
good for pathology, radiology, and management plan, and
somewhat weaker for the clinical, holistic inputs, and
clinical collaboration, warranting further testing on a larger
sample.
Phase 3: Inter-Assessor Reliability and Feasibility
in the Use of the Tool (Objective C)
Inter-assessor agreement on MODe-Lite was examined
using kappa coefficients for categorical (i.e., the individual
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MDT-MODe Lite Copyright 2020 © Lamb Soukup. Copyright license: CC-BY-NC-ND. Description of items and how to score can be obtain from Lamb. Please reference as follows: Lamb
BW, Miah SM, Soukup T. Development and evaluation of an observational assessment tool adapted for use in routine clinical practice.
FIG. 1. Copy of the MODe-LITE tool. MODe-LITE Copyright 2021  Soukup Lamb under CC-BY-NC-ND
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items of MODe-Lite) and ICCs for continuous (i.e., the
global scores) variables on a subsample of 60 cases (40 %
of the total). Good reliability between the two raters
(B.W.L. and S.M.) was evident across all six domains, with
the ICCs for global score higher than the generally
accepted 0.7026 and the kappa coefficients for individual
items ranging from moderate to almost perfect agreement.
The tool was reported feasible and straightforward to use
by both assessors.
A post-scoring data-review session was undertaken to
understand how the scoring of the tool could be improved
in the two domains that initially appeared to have lower
ICCs: holistic input (0.64) and management plan (0.68).
Disagreement with regard to scoring of holistic information
was perceived to be a limitation of data quality, specifi-
cally, sound quality. Scoring of information on holistic
aspects of care in MODe-Lite was not anchored to specific
members of the MTB, nor to specific terminology, and
therefore was easier for observers to miss when the sound
quality of the video recordings was poor.
Another limitation of data quality was disagreement on
scoring of the management plan. The observers noted that
the MTBs used abbreviations for follow up plans (e.g.,
abbreviation for a follow-up pathway) that were specific to
that team or organization. However, abbreviations or jar-
gon relating to the disease or investigations are more
universally understood (e.g., CT scan). Locally specific
abbreviations might not be understood by external
assessors.
After review and discussion of specific cases of dis-
agreement, the majority were settled in agreement, and
revised scores for ICC were recorded (Table 5). A minority
TABLE 3 Item convergent
validity, reliability, and external
validity for the MODe-Lite
MODe-lite domain n MODe-Lite global score MODe global score MeDiC global score
R P value R P Value R P Value
Clinical input 146 0.60 0.001 0.41 0.001 0.12 0.159
Holistic input 146 0.58 0.001 0.43 0.001 0.39 0.001
Clinical collaboration 146 0.70 0.001 0.51 0.001 0.38 0.001
Pathology 146 0.25 0.002 0.12 0.149 0.03 0.740
Radiology 146 0.54 0.001 0.52 0.001 0.33 0.001
Management plan 146 0.77 0.001 0.44 0.001 0.25 0.003
MODe-LITE global score 146 – – 0.71 0.001 0.41 0.001
MODe, Metric for the Observation of Decision-making; MODe-Lite, user-friendly version of the MODe;
MeDiC, Measure of Case-Discussion Complexity; n, sample size; r, Pearson’s correlation; P, statistical
significance value (P\ 0.05)
TABLE 4 External validity and internal consistency for MODe-Lite against the original MODe toola
MODe item
MODe-LITE domain n r P value r P value r P value Cronbach’s alpha
Patient history
Clinical input 146 0.52 0.001 0.64
Psychosocial information Comorbidity information Patient views
Holistic input 146 0.36 0.001 0.46 0.001 0.28 0.001 0.66
Surgeon input Oncologist input Nurse input
Clinical collaboration 146 0.21 0.012 0.48 0.001 0.45 0.001 0.58
Radiologist input Radiologist information
Radiology 146 0.53 0.001 0.76 0.001 0.80
Pathologist input Pathology information
Pathology 146 0.76 0.001 0.78 0.001 0.90
Decision reached
Management plan 146 0.56 0.001 0.71
MODe, Metric for the Observation of Decision-making; MODe-Lite, user-friendly version of the MODe; n, sample size; r, Pearson’s correlation;
P, statistical significance value (P\ 0.05)
aA traffic-light system for a visual guide was used to indicate how well each set of MODe items relates to its corresponding MODe-Lite domain:
green represents good internal consistency, and amber represents fair internal consistency.
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of cases remained in disagreement between the observers,
which related to perceived differences in the application of
the scoring, particularly for management plan. Specifically,
the word ‘‘treatment’’ was thought to apply only when
treatment was recommended. Where patients were found
not to require treatment, it was thought that the word
‘‘management’’ was more appropriate. Otherwise, despite
the formation of a good management plan, a top score
could not be awarded. The assessors agreed on a slight
modification of the anchor behavior for management plan,
with a change in wording from ‘‘treatment options,’’ to
‘‘management options.’’
The change from scoring a Likert scale of 5 points to 3
points was thought by the observers to make scoring easier.
The anchor behaviors of MODe-Lite were of a more cat-
egorical nature (with scores assigned for the accumulation
of different types of behaviors) than those of MDT-
MODe,7 which required users to quantify a given amount
of a composite behavior (e.g., contribution of a particular
speciality). The assessors found that it was easier, and
therefore quicker, to apply a score to MODe-Lite than to
the original MODe. This increased ease of scoring was
thought by the observers to be important when several
domains were scored in real time and made the task more
feasible.
DISCUSSION
The current study aimed to improve the utility of an
existing observational assessment tool (MDT-MODe)7 by
designing and validating a shorter version of MODe (i.e.,
MODe-Lite) for use in routine clinical practice. We
demonstrated good item-content validity, with the con-
vergent validity of our H1 supported. The MODe-Lite
domains correlated positively with the relevant items of the
original MODe,7 in line with the factor model proposed in
previous research (objective A).9 In addition, H2 was
supported as we were able to demonstrate external validity
against the MeDiC tool20,21 (objective B) in line with
previous research that used MODe.12 We also demon-
strated good inter-assessor reliability and feasibility in the
use of the tool (objective C). Internal consistency was good
across all MODe-Lite domains, but clinical input, holistic
input, and clinical collaboration showed weaker consis-
tency, warranting further testing with a larger sample.
Although clinical input, holistic input, and clinical col-
laboration had loaded onto a single factor in previous
research, suggesting that they should be grouped into a
single domain for scoring,9 based on the evidence and the
needs of the tumor boards, their separation is critical for
adequate team assessment and provision of feedback for
quality improvements.10,11 For instance, evidence shows
that holistic inputs tend to be underrepresented in the
decision-making of tumor boards, yet are essential for their
ability to reach4,9 and subsequently implement a treatment
recommendation,35,36 and are encouraged by the relevant
guidelines.31,37 Therefore, scoring of the holistic input
separately and pulling it apart from the other three items
can help in assessing how well a team covers this aspect
and how to improve it. Similarly, evidence shows that
clinical collaboration of tumor boards can be suboptimal.
However, it is critical for effective decision-making,4,9,35,36
and thus, it is important that this item be scored separately
as well.
STUDY IMPLICATIONS
The MODe tool7 has been used in studies across many
tumor types and applied to different languages in different
countries (see Table 1). Its broader impact on the literature
surrounding MTB transformation has been demonstrated
by the number of citations accrued by the development
studies. The MODe has been used by researchers as a
stand-alone assessment method to increase understanding
of team behaviors in MTB meetings11–13 and also as a
method alongside other performance metrics in complex
interventional studies to assess the impact of interventions
on aspects of team decision making.10 This flexibility has
undoubtedly increased the uptake of the tool.
Use of the MODe,7 has come largely from dedicated
academics with a specific interest in improving MTB
processes. Since its development, the UK has had a move
away from the implementation of top-down improvement
TABLE 5 Inter-assessor reliability coefficients for the MODe-Lite
domains
MODe-Lite domain n Assessor 1 Assessor 2 Kappa
M SD M SD
Clinical input 60 1.98 0.73 1.95 0.77 0.64
Holistic input 60 1.20 0.48 1.25 0.54 0.89
Clinical collaboration 60 1.67 0.75 1.53 0.62 0.60
Radiology 60 2.00 0.97 1.95 0.99 0.85
Pathology 60 2.63 0.66 2.70 0.65 0.70
Management plan 60 2.03 0.74 1.82 0.77 0.97
Global score 60 11.52 2.50 11.20 2.45 0.84a
MODe, Metric for the Observation of Decision-making; MODe-Lite,
user-friendly version of the MODe; n, subsample size; M, mean; SD,
standard deviation
aIntraclass correlation coefficient (ICC) values. Kappa coefficients
can be interpreted as follows: 0.21–0.40 (fair agreement), moderate
agreement (0.41–0.60), substantial agreement (0.61–0.80), almost
perfect agreement (0.81–1.00).
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in MTB transformation toward the adoption of solutions
geared more to local challenges.38,39,40,43 A need therefore
exists to equip health care professional to understand their
own MTBs, and to identify solutions that work for them in
their unique setting. Findings have clearly shown that the
MODe requires a certain level of training before ratings
can be reliably undertaken.7 It has become clear from our
own experience of training health care professionals to use
MTB improvement tools that such tools must have a short
learning curve and be capable of quick administration in
real-life MTB meetings.
The current study demonstrated that adequate reliability
scores can be achieved by novice raters during a shorter
period, offering improvements in feasibility. This suggests
that MODe-Lite may offer health care professionals a
simpler tool with a shorter learning curve that maintains the
validity of the original tool. Further research is needed,
however, for direct comparison of the learning curve and
workload between MODe and MODe-LITE.
The ability of health care professionals at the grass roots
to take ownership of improving the services they provide
for patients is of growing importance. In the UK, MTBs
have been urged to change the way they work in order to
save a rapidly overburdened service.38,43 Guidance has
been issued recommending that teams use evidence-based
tools to understand and improve the way they work in order
to meet local need.38,43 In the United States (and else-
where), in which health care policy is less top-down,
MODe-Lite offers a good starting point for an attempt to
figure out team-based cancer care and enable teams to take
a scientific approach to MTB development.
As Fig. 2 suggests, MODe-Lite also could be used in a
variety of ways, from stand-alone assessment of current
working practices to a method alongside a more compre-
hensive tool kit.12,20,41–43 Either way, we recommend that
potential assessors undertake training in the use of the tool
that involves (1) learning about the tool, the scoring sys-
tem, behavioral anchors, and how to mitigate biases given
that this is an observational tool, (2) practicing scoring on
real cases, either in a video format or in person (or both if
available) and assessing inter-rater reliability in the pro-
cess, and (3) scoring the cases for data collection purposes
again using either a video or an in-person format once
proficiency is reached (as assessed by adequate inter-rater
reliability). Therefore, we recommend that users of MODe-
Lite do the same as for the original MODe and hypothe-
size, given our findings, that the period of learning will be
shorter than for the original tool.
An organization wishing to start using MODe-Lite
might use video recordings for training and assessing
interrater reliability if they are available. If videos are not
available, the novice assessor can practice in real meetings.
Either way, once a high level of interrater reliability is
reached ([0.70),26 the assessor can begin to use the tool in
real meetings for data collection and evaluation.
Streamlining of MTB processes, and MTB meetings
specifically, is intended to allow more time for discussion


























Tools for continuous MDT self-
reflection & team building:
MDT-MODe: assesses specialist
contributions to each patient review;
identifies areas that tend to get
neglected and/or professional groups
that tend to not speak up at meetings
MDT ATLAS: assessed MDT chairing &
leadership skills; identified areas for
team leadership skills development
MDT FIT: allows holistic team
assessment & reflection and facilitates
team building
FIG. 2. Schematic representing the phases of the multidisciplinary team working with application of quality-improvement tools. Reprinted with
permission from43
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approach. The MODE-Lite tool presents two potential
opportunities for professionals seeking to undertake MTB
improvement using evidence-based tools. First, concen-
tration on those cases that benefit from a multidisciplinary
approach endorses this way of working, and therefore
places a requirement on MTBs to ensure that they are
functioning as well as possible. Complex cases, by their
nature, often have comorbidities or psychological or social
challenges, as evidenced by the MeDiC tool with its
stakeholder-driven development. 20 Decision-making in
MTB meetings has consistently been found to underuse this
type of information, to the detriment of patients.1,5 Simi-
larly, MTB meetings are generally dominated by a small
number of team members, with exclusion of others, par-
ticularly specialist cancer nurses.1,9 Nurses have a pivotal
role in the care of cancer patients, and their input into the
decision-making process in MTB meetings is critical to
ensure the highest standard of care.1 In practical terms,
deficiencies in information-sharing or under-representation
of particular specialities at the MTB would show up as
suboptimal scores for particular categories. Therefore,
MODe-Lite might allow MTBs to quickly gain an under-
standing of the strengths and weaknesses of their MTB
meeting processes, and how they can be improved.
Second, streamlining is intended to reduce the time and
manpower required for MTB meetings. In addition, regular
auditing and assessment using evidence-based tools is
stipulated in guidance in the UK38 Streamlining therefore
becomes both a driver and an opportunity to use tools to
investigate and improve the way they work. For profes-
sionals with an interest in quality improvements, MODe-
Lite provides a potential solution that gives a feasible, yet
robust means of self-assessment.
Digitization of quality improvement tools, together with
their integration into electronic medical record systems,
will be important going forward. This will further improve
feasibility and also facilitate aggregation of data over time
across different tumor types or between MTBs. This will
allow teams to better appreciate patterns of practice over
time or space, perhaps in response to interventions
designed to improve performance. It also may help com-
parison between different MTBs, facilitating bench-
marking or accreditation.
STUDY LIMITATIONS
Our findings need to be interpreted within certain limi-
tations. First is the Hawthorne effect. In line with the
ethical and regulatory approvals of participating NHS
organizations in the UK, informed consent from team
members was sought, which meant that they knew they
were going to be filmed (i.e., there was no deception). To
counteract this, a long-term approach to filming was
adopted. Each team was filmed for 3 months. The first two
meetings of each team were excluded from the analysis.
The filming was performed discretely using a small GoPro
camera, and the evaluators all were trained in use of the
tools, which they scored in pairs blinded to one another’s
observations.
Second, although tumor boards occur and are mandated
for accreditation across various countries (e.g., American
College of Surgeons Commission on Cancer), this study
was conducted entirely in the United Kingdom. In large
part, the domains identified through this rigorous study are
fundamental to high-quality cancer care regardless where
the care is delivered, although further validation in other
cancer care systems is required. Finally, this study repre-
sents the most common cancers within the English NHS.
Replication of the study in other cancers, teams, and health
care systems is needed to support further generalizability of
the findings.
CONCLUSIONS
The MODe-Lite is a scientifically developed and vali-
dated tool for use by health care professionals to assess and
improve MTB meetings. The learning curve appears to be
shorter than for the previous version, with maintenance of
its robust psychometric properties. It can be used alone or
in conjunction with other quality improvement interven-
tions to improve the care of cancer patients. Further work is
needed to digitalize MODe-Lite and other quality
improvement tools.
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